TNFRSF18 and neoplasm: In this present study, the efficacy of systemically administered GITR agonist and PD-1 blockade was augmented by peritumoral DR-pulsed-BMC/DC administration independently of antigen presentation and through local alterations of T-cell effector functions within the tumor.